【24h】

Hypercalcaemia - presentation and management

机译:高钙血症 - 展示和管理

获取原文
获取原文并翻译 | 示例
           

摘要

Hypercalcaemia is a common disorder normally caused by primary hyperparathyroidism (PHPT) or malignancy. A proportion of cases present as an emergency, which carries a significant mortality. Emergency management of hypercalcaemia is based on intravenous rehydration with normal saline but when this is inadequate, bisphosphonate therapy is used; more recently the novel anti-resorbtive agent denosumab has been shown to have a useful role in treatment. It is estimated that up to 10% of all cases of PHPT presenting under the age of 45 years have an underlying genetic predisposition; nine potentially causative genes are now recognised and may be screened in routine clinical practice. Although parathyroidectomy is the only curative treatment for PHPT, this is indicated in a minority of cases. Many cases can be adequately managed conservatively and guidance from the 4th international workshop on the management of asymptomatic PHPT has recently been updated in a consensus statement.
机译:高钙血症是通常由原发性甲状旁腺功能亢进(PHPT)或恶性肿瘤引起的常见疾病。 作为紧急情况的案例比例呈现出显着的死亡率。 高钙血症的急诊管理是基于静脉注重正常盐水,但是当这不充分时,使用双膦酸盐治疗; 最近,新型的抗逆反应剂Denosumab已显示在治疗中具有有用的作用。 据估计,在45岁以下的PHPT患者中最多10%具有潜在的遗传易感性; 现在认识到九个潜在的致病基因,并且可以在常规临床实践中筛选。 虽然甲状旁腺切除术是PHPT唯一的治疗方法,但这在少数病例中表明。 许多情况可以保守地保守,并从第四届国际讲习班关于无症状PHPT管理的指导最近在共识声明中更新。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号